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Interest in use of the psoralen compounds as a
possible prophylactic against cancer of the skin
followed several years of their empirical use in
the treatment of vitiligo. These early efforts to
confirm impressions of clinical usefulness were
disappointing and resulted in diversion of the
principal research efforts toward elucidation of
basic mechanisms of photodynamic response of
the skin, with the empirical investigations as-
suming a position of lesser but still complement-
ary importance.
By 1956 a working hypothesis had evolved of
possible practical significance. The considerations
leading to this hypothesis were described in a
preliminary report of these trials (1): one, pa-
tients using psoralen for vitiligo reported pro-
tection against sunburn (2); two, controlled
experiments showed primary effects of psoralen,
whether administered orally or topically, to be
potentiation of the skth in its erythema and pig-
mentation responses to ultraviolet irradiation
(3); three, the apparent protective effect of psora-
len against sunburn could be explained as a
secondary result of increased activity of the skin
in raising its normal defenses by thickening of
the stratum corneum and, finally, other layers,
which then became effective against subsequent
ultraviolet irradiation; four, experiments with
ultraviolet induced skin cancers in albino mice
(4) were interpreted as showing that a high dose
of psoralen had augmented skin responses to
ultraviolet irradiation beyond physiologically
tolerable levels, causing trauma and subsequently
triggering malignant growth. On the other hand,
a low dose had been sufficient to stimulate an
increase in the normal protective responses of
the skin against the carcinogenic action of the
subsequent irradiation without exceeding physi-
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cal tolerance. It was not possible to specify hosv
this secondary protective effect might be operat-
ing, since the mechanism was not known for
either the psoralen activity or the carcinogenesis.
Since the mice were albino it was assumed that
at least the pigment factor could be ruled out as
having a protective effect; five, epidemiologic
surveys based on cancer registries brought out
that skin cancers are more prevalent on exposed
areas of the head) neck and hands among light
skinned people in high, dry and sunny climates
than elsewhere (5).
While psoralen was no longer believed to afford
any primary shielding in the sense of a simple
sunscreen or ultraviolet absorber, it was reasoned
that at low dose levels it would, without causing
trauma, increase physiological pigmentation and
cornification of the epidermis sufficient to filter
out a significantly increased amount of ultra-
violet energy. A small daily dose of oral psoralen
for an outdoor worker might build up in the skin
a natural protective covering. It was hypothesized
that reduction of cumulative ultraviolet to a
point below the carcinoma triggering level could
be attained by this approach.
Low toxicity and good human tolerance of
orally administered psoralen in the form of
methoxsalen in low doses had been demonstrated
(6). While the mechanism of action was not
understood, it was reasoned that if cancer pro-
tection could possibly eventuate, some risk was
acceptable. Accordingly, a clinical trial was set
up.
METHOD AND MAIEEJAL5
A community (El Paso, Texas) was located in
which a functioning cancer registry, which in-
cluded dermatologists' offices as well as clinics,
laboratories and hospitals, showed high incidence
of cancer of the skin of the face and hands, with
some 1,500 living cases on the register. It also
happened to be a high, dry, sunny locale inhabited
by 2 contrasting dermatologic groups, one lightly
and the other rather darkly pigmented. A small
group of dermatologists who see a large propor-
tion of the skin affections of the locale agreed to
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conduct a trial study under our direction. We
supplied the drugs, special study forms, and a
clerk to work in their offices interviewing the
patients, recording the data, dispensing the drugs,
monitoring the follow-up, and generally assuming
the innumerable small extra burdens imposed by a
study. It cannot be overemphasized that the suc-
cess of a clinical trial depends on provision of
effective staff work of this sort.
All patients who already had 2 or more skin
cancers or keratoses on head, neck or hands and
were willing to enter the study were admitted.
Once admitted they were given a study number
and study interview which included inventory
with photographs, of all lesions present, and skin
color readings on the reflectance meter. They
were given a 3 months' supply of the medication
and instructions for its use. At 3 months intervals
they returned for examination by the physician,
follow-up interview and photographs, and refill
of their drug supply.
Control of the drug effect was obtained by use
of 2 different psoralen compounds, A and B, which,
if our hypothesis was even approximately correct,
would produce distinctly different prophylactic
effects. The 2 "drugs" were allocated to the pa-
tients individually and blindly according to a
prearranged drawing of random numbers. They
were supplied by the manufacturer in identical
appearing bottles and capsules bearing oniy the
general "psoralen" name and the name and num-
ber of the patient. Only after our analysis of the
results had been completed and our conclusions
drawn did we decode and relate effects to the spe-
cific drugs. The patients were all told that theywere
TABLE I
Summary of results
Drug Drug Total
Patients entered into study 86 87 173
Outdoor occupation 61 64 125
Indoor occupation 25 23 48
Dropped out of study 15 16 31
Number of 3 months
examinations 370 328 698
Number of reports of new
lesions (Counting patients
only once) 60 59 119
Outdoor occupation 51 50 101
Indoor occupation 9 9 18
Number of new lesions ob-
served (Counting lesions
only once) 122 142 264
Increased sunburn observed
(at 3 months) (X2 = 10.4
p = 0.001) 42 27 69
Increased tanning observed
(at 12 months) (X2 = 39
p=0.05) 9 3 12
being given a new drug which might cause in-
creased tanning and possibly prevent sunburning
and skin cancers. They took 20 mg. daily at break-
fast time, the uptake time being about 2 to 4 hours.
Figure I
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Criterion of effect was the number of new lesions difference of as much as 25 percentage points, e.g.
occurring during each trial period (3 months). 50 per cent versus 25 per cent having new lesions,
It was expected that about half of the patients between the 2 treatment groups. The sequential
would produce new lesions in a given period, plan gave a 95 per cent chance of detecting an
The statistical control unit for the trial moni- adverse effect and a 90 per cent chance of detecting
tored the records sequentially so that the trial a prophylactic effect if such existed, and permitted
could be stopped as soon as a statistically signifi- us to stop the trial as soon as such an effect became
cant decision became possible. Patients on the evident.
2 contrast drugs were paired randomly and ana- For this part of the trial, the immediate effects
lyzed sequentially following the Bross (7) plan part, we anticipated following about 500 patients
for detection of a moderate difference. This plan for 2 years. To initiate studies of latent effects
guaranteed a good chance of detecting a true we provided for 100 of the patients to be selected
TABLE II
Study patients classified by drug, age, sex, occupation and number of initial lesions
Outdoor Occupations Other Occupations Total
Age/Drug 6 or More Less than 6 6 or More Less than 6Lesions Lesions Lesions Lesions
________ ____________ Total Total Male Female Total
Male Female Male Female Male Female Male Female
20—29 2 — — 1 3 1 — 1 2 3 2 5
30—39 11 — 4 1 16 1 2 5 3 11 21 6 27
40—49 30 — 14 1 45 1 4 1 2 8 46 7 53
50—59 20 1 11 1 33 5 6 5 1 17 41 9 50
60—69 12 2 6 1 21 4 2 1 2 9 23 7 30
70—79 2 1 1 — 4 1 — — 1 4 1 5
80—89 3 — — — 3 — — — — — 3 — 3
Total ...... 80 4 36 5 125 13 14 12 9 48 141 32 173
Drug A... .
Drug B... .
Total
41
39
80
—
4
4
17
19
36
3
2
5
61
64
125
7
6
13
7
7
14
6
6
12
5
4
9
25
23
48
71
70
141
15
17
32
86
87
173
TABLE III
New lesions by period, occupation and initial lesion status
Visit
3months
6 months
9months
l2months
l5months
l8months
2lmonths
24 months
Total New Lesions Patients by Occupation Patients By Initial Lesion Status Total
Drug A
31
22
16
13
15
6
8
11
Drug B
34
34
12
28
21
9
2
2
Ut oor
Drug Drug
A B
8 9
13 11
7 8
7 9
7 8
4 2
3 2
2 1
t er
Drug Drug
A B
3 2
1 3
2 1
— 1
2 1
— 1
—
1 —
6 or More
Lesions
Drug Drug
A B
9 8
9 11
9 6
4 6
4 7
4 2
3 2
2 1
Less Than S
Lesions
Drug DrugA B
2 3
5 3
— 3
3 4
5 2
— 1
— —
1 —
Drug
11
14
9
7
9
4
3
3
Drug
11
14
9
10
9
3
2
1
Total 122 142 51 50 9 9 44 43 16 16 60 59
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TABLE IV
Summary of report of new lesions by visit and by drug
Total 122 142 264 60 59 119
at entry into the study as long-termers who would
stay in a continued study for 5 years or more. By
comparing rates of new lesions in their first,
second, third and up to twentieth 3 months period
we hoped to get information on latent and cumu-
lative effects of the drugs.
The median induction time for the appearance
of new lesions in all the patients in the registry
with more than 1 lesion on the exposed areas of
the head, neck and hands was 18 months. It was
therefore expected that 50 per cent of the patients
would develop new lesions in 18 months regardless
of drug. It turned out that 61 per cent of the pa-
tients on drug A developed new lesions in 18
months and 63 per cent on drug B.
Patients were entered into the study from June
3, 1957, through January 22, 1959, and follow-np
continued until the Bross stopping rule (7) in-
dicated a decision had been reached. Using the
criterion new lesions in outdoor workers at 12
months point of treatment, the stop-trial decision
was reached in January, 1959, with the 24th non-
tied pair of patients (figure 1) out of 42 pairs
treated 12 months. Five of the pairs had indoor
occupations and should not have been entered into
the study. Thirteen pairs were tied in number of
new lesions at 12 months. These 18 pairs thus
contributed nothing to the stop-trial decision, but
are included in the analysis of results.
RESULTS
The stop rule led to the verdict of no impor-
tant difference between drug A and B. The results
are summarized in Table I.
The conclusion with respect to prophylactic
effect of the psoralen treatment is negative. The
2 drugs had essentially equal effects. Decoding
revealed that the drugs were: A: 20 mg methox-
Reason
Nausea
Nausea and other reasons.
Uncooperative
Inconvenient
Diarrhea
Ulcers
Other reasons
Not Stated
Total drop outs for
reasons
Not followed full 24 months.
In study 24 months
Pts. in Study PatientsExamined
Total Number
New Lesions
New Lesions per
Patient Nombee Reportsof New Lesions
Visit
Initial
3 months
6 months
9 months
12 months
15 months
18 months
21 months
24 months
No. New Lesions
per Pt. with any
New Lesions
Drug Drug Total Drug Drug Drug
86 87 173
75 69 144 64 61 31
70 63 133 58 56 22
61 52 113 45 38 16
55 46 101 42 42 13
44 42 86 34 35 15
31 30 61 26 26 6
20 17 37 17 15 8
12 13 25 10 8 11
Deug
B
34
34
12
28
21
9
2
2
Drog TotalTotal Drug Drug Total Drug Drug Total Drug
65 0.4 0.5 0.4 11 11 22 2.8
56 0.3 0.5 0.4 14 14 28 1.6
28 0.3 0.2 0.2 9 9 18 1.8
41 0.2 0.6 0.4 7 10 17 1.9
36 0.3 0.5 0.4 9 9 18 1.7
15 0.2 0.3 0.2 4 3 7 1.5
10 0.4 0.1 0.3 3 2 5 2.7
13 0.9 0.2 0.5 3 1 4 3.7
3.1
2.4
1.3
2.8
2.3
3.0
1.0
2.0
3.0
2.0
1.6
2.4
2.0
2.1
2.0
3.3
TABLE V
Drop outs by reason
Drug
6
2
1
2
4
15
58
13
Drug
3
1
4
1
1
5
1
16
59
12
Total
9
3
4
1
1
3
9
1
31
117
25
Total 86 87 173
salen daily by mouth; B: 0. mg. methoxsalen
daily by mouth (inert pill). Psoralen failed to
demonstrate a skin cancer prophylactic effect.
DISCU55ION
The significant increase in sunburn and tan-
ning5 obtained on the psoralen treatment affords
evidence of drug adherence and effective dose.
The stopping rule was designed to make the trial
sensitive to substantial drug differences, but not
* Clinician-appraised, confirmed by reflectance
meter readings and color photographs taken on
all patients.
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small differences. The remarkably close equality
of the new lesion experience in the 2 groups sug-
gests that if there is any prophylactic effect of
the psoralen it must be extremely slight.
Some further details of interest to the clinician
are shown in Tables II through V. Table II
shows the distribution of patients by age, sex,
occupation, drug allocation, and number of
initial lesions (lesions observed before entry
into study). Table III gives the record of inci-
dence of new lesions, by successive periods of
treatment. Outdoor occupations included 72
percent of the patients, but 85 percent of the
reports of new lesions, lending support to the
initial hypothesis of relationship between solar
exposure and skin cancer induction. The number
of females is so small, and is concentrated so
heavily in occupations not subject to solar ex-
posure, that the sex breakdown is not continued
in subsequent tables.
In Table IV incidence rates of new lesions per
patient examined and per patient with any new
lesions are given. These rates appear to be es-
sentially constant through the 24 months of the
trial and equal for the drug treatments.
Finally, an analysis of the dropouts is given in
Table V. Fifteen patients were dropped from
drug A and 16 from drug B. Dropouts were dis-
tributed evenly between the 2 drugs, indicating
the failures were due to factors other than the
drug. Current sequential monitoring emphasized
the similarity of response of patients to drugs A
and B. By the time patients had been in the study
1 year it was apparent that no differences in
response were measurable by this form of study,
and follow-up was discontinued on 117 patients
short of 24 months. Twenty-five of the entered
patients remained in the study for 24 months.
The difficulty of carrying out a long term study
and maintaining physicians' and patients' in-
terest when response to either of a pair of drugs
is so similar, is demonstrated in a study of this
type. Such a study does dissipate false enthu-
siasms based on clinical impressions that a drug
is efficacious.
sUMMARy
1. Effectiveness of oral 8-methoxypsoralen as a
prophylactic against skin cancer was tested in a
double-blind controlled trial. Subjects were 141
middle aged men, and 32 women, primarily in
outdoor occupations, who had already had at
least 1 histologically verified skin cancer.
2. Methoxsalen was administered at the rate
of 20 mg daily by mouth, taken in the morning.
Patients were seen every 3 months for inventory
of new lesions.
3. Side effects were minimal. Dropouts were
equally frequent in methoxsalen and inert con-
trol series.
4. Effective dose level and patient adherence
were confirmed by observation of the expected
primary effect, increased sunburn, and later,
tanning, in the methoxsalen patients. Increased
sunburn and tanning were the only significant
differences obtained in the 2 series.
5. By the time 24 controlled pairs of patients
had been followed 1 year and the results analyzed
sequentially, the decision was reached that there
was no difference between the methoxsalen pa-
tients and their inert drug treated controls in the
incidence of new lesions. At this time 12 patients
had been treated for 2 full years on methoxsalen
and 13 on control.
6. It is concluded that methoxsalen in humanly
tolerable tanning doses has no immediate effect
on incidence of new lesions of skin cancer.
Whether larger doses or treatment over a longer
period than 2 years might be effective cannot be
determined from this trial.
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